Clinical Outcomes of Lu-177-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy

Thomas W. Barber*, Aviral Singh, Harshad R. Kulkarni, Karin Niepsch, Baki Billah, Richard P. Baum

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)955-962
Number of pages8
JournalJournal of Nuclear Medicine
Volume60
Issue number7
DOIs
Publication statusPublished - 1 Jul 2019

Keywords

  • Lu-177-PRLT
  • lutetium
  • prostate-specific membrane antigen
  • radioligand therapy
  • chemotherapy
  • INCREASED SURVIVAL
  • DOCETAXEL
  • PSMA
  • MITOXANTRONE
  • ABIRATERONE
  • PREDNISONE
  • ENZALUTAMIDE
  • CABAZITAXEL
  • SAFETY

Cite this